HBW
MDCX

Hazlett, Burt & Watson’s Medicus Pharma MDCX Stock Holding History

Hazlett, Burt & Watson’s Portfolio MDCX Stock Details MDCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
425
– – ﹤0.01% 962
2026
Q1 		$0 Hold
425
– – ﹤0.01% 963
2025
Q4 		$1K Buy
+425
New +$910 ﹤0.01% 908

Other funds holding MDCX

ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

Hazlett, Burt & Watson's MDCX Position: Q2 2026 in Review

Hazlett, Burt & Watson held its Medicus Pharma (MDCX) position steady in Q2 2026 at 425 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #962.

Hazlett, Burt & Watson first reported a position in MDCX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1K in Q4 2025. 6 funds tracked by Wall St. Rank hold MDCX as of Q2 2026.

  • Hazlett, Burt & Watson held 425 shares of Medicus Pharma worth $0 as of Q2 2026.
  • Hazlett, Burt & Watson left its Medicus Pharma share count unchanged in Q2 2026.
  • Medicus Pharma made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #962 holding.
  • Hazlett, Burt & Watson first reported a position in Medicus Pharma in Q4 2025 and has held it in 3 quarters since.
  • Hazlett, Burt & Watson's Medicus Pharma position peaked at $1K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Medicus Pharma as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.